Targeting ZBTB21: A Potential Drug Approach (G49854)

Target Name: ZBTB21

NCBI ID: G49854

ZBTB21

Targeting ZBTB21: A Potential Drug Approach

ZBTB21 (Zinc Finger Transmembrane Barrier 21) is a protein that is expressed in various tissues throughout the body. It is a member of the Zinc Finger Transmembrane Barrier (ZBT) family, which is a family of proteins that play a crucial role in cellular signaling and membrane structure. ZBTB21 is unique due to its structure and function, and it has been identified as a potential drug target and biomarker.

The ZBTB21 protein is a transmembrane protein that is expressed in various tissues, including the brain, heart, and kidneys. It is characterized by its ability to form a stable transmembrane barrier, which is important for maintaining the integrity of these tissues. ZBTB21 functions as a protein that can interact with various signaling molecules, including transcription factors, hormones, and neurotransmitters.

One of the unique features of ZBTB21 is its ability to form a stable transmembrane barrier that is impermeable to most molecules. This barrier allows ZBTB21 to regulate the movement of substances into and out of cells, which is essential for maintaining the homeostasis of these cells. ZBTB21 has been shown to play a role in the regulation of ion and solute transport, as well as the maintenance of cell signaling pathways.

In addition to its role in cell signaling, ZBTB21 has also been identified as a potential drug target. Its unique structure and function make it an attractive target for small molecules, which can be used to modulate its activity. This has led to a significant interest in the development of drugs that target ZBTB21.

One of the first drugs that was shown to target ZBTB21 was a small molecule called TK-158. TK-158 is a compound that binds to a specific epitope on the ZBTB21 protein. When TK-158 binds to ZBTB21, it causes a conformational change that results in the loss of ZBTB21's transmembrane barrier. This loss of barrier allows TK-158 to interact with ZBTB21 and modulate its activity.

The results of TK-158 experiments have shown that TK-158 is effective in reducing the activity of ZBTB21 in cell signaling pathways. This suggests that TK-158 could be a useful drug for the treatment of various diseases that are characterized by the over-activity of ZBTB21.

Another potential drug that targets ZBTB21 is a compound called WT1-22. WT1-22 is a small molecule that binds to a different epitope on the ZBTB21 protein. Unlike TK-158, WT1-22 does not cause a conformational change when it binds to ZBTB21. Instead, it appears to modulate ZBTB21's stability by affecting its expression level.

The results of WT1-22 experiments have shown that WT1-22 is effective in inhibiting the activity of ZBTB21 in cell signaling pathways. This suggests that WT1-22 could be a useful drug for the treatment of various diseases that are characterized by the over-activity of ZBTB21.

In conclusion, ZBTB21 is a unique protein that plays a crucial role in cellular signaling and membrane structure. Its ability to form a stable transmembrane barrier and its unique structure and function make it an attractive target for small molecules. The development of drugs that target ZBTB21 has the potential to revolutionize our understanding of cellular signaling and the treatment of various diseases.

Protein Name: Zinc Finger And BTB Domain Containing 21

Functions: Acts as a transcription repressor

The "ZBTB21 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ZBTB21 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets